Dr Kate Cuschieri is the Director of the Scottish HPV Reference laboratory and holds an Honorary Senior Lectureship at the University of Edinburgh. She is an expert on HPV detection assays and use of molecular tests in cervical screening. Also is the Director of Scottish HPV Archive and is recognised as a key opinion leader in HPV diagnostics and screening in the UK and internationally. (http://www.path.ed.ac.uk/research/dr-kate-cuschieri)

Dr Ramya Bhatia has a PhD from University of Edinburgh in host interactions of HPV virus. She is currently a researcher in HPV Research Group, Edinburgh and the Manager of the Scottish HPV archive. She is a member of SHINe and has extensive knowledge of the molecular biology of the virus and its cellular interactions.

Professor Sarah Howie is Professor of Immunopathology at the University of Edinburgh. She is an experienced immunologist, who has published over 130 papers and has worked for many years on measuring immune responses in chronic inflammatory diseases. Together with Kate Cuschieri, she holds the grants that have led to the development of the CINck Test. (http://www.cir.ed.ac.uk/investigator/Professor-Sarah-E-M-Howie)

Dr Giles Dudley (Sunergos Innovations) has provided operational support during the early research phase of the project and will continue to do so for the next 20 -24 months. He is ideally placed to carry out the role, as the majority of Precidar Dx research activity will be subcontracted back to the university.

Sandy Primrose is a non-executive director (NXD) of Fios Genomics, Arrayjet Ltd, Cellexus Ltd and Arquer Diagnostics Ltd. He represents The London Technology Fund and Esperante Ventures. He is also on the Board of Immune Targeting Systems Ltd. Sandy is the senior partner at Business and Technology Management, a biotechnology and healthcare consultancy practice. P(https://uk.linkedin.com/pub/sandy-primrose/7/333/583)